2Jamieson PM, Nyirenda M_J, Walker BR, et al. Interactions between oestradiol and glucocorticoid regulatory effects on liver- specific glucocortieoid- inducible genes; possible evidence for a role of hepatic llbeta- hydroxysteroid dehydrogenase type 1. J Endocrinol 1999;160(1) :103- 109.
3Lundgren M, Buren J, Ruge T, et al. Glucocorticoids down -regulate glucose uptake capacity and insulin - signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 2004 ;89(6) .-2989- 2997.
4Delaunay F, Khan A, Cintra A, et al. Pancreatic beta ceils are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997;100(8) :2094- 2098.
5Pauthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 2004 ;49(4) : 139 - 141.
6Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid - related diabetes mellitas. Rheum Dis Clin North Am 1999 ;25 (3) : 489 - 505.
7Gurwitz J, Bohn R, Glynn R, et al. Glucocorticoids and the risk for initiation of hypoglycemia therapy. Arch Intern Med 1994; 154(1):97- 101.
8Midtvedt K, Hjelmesaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reductionand with drawal. J Am Soe Nephrol 2004 ; 15 (12) : 3233 - 3239.
9Braithwaite S,Barr W, Thomsa J. Diabetes management during glucocorticoid therapy for nonendocrine disease. Endocrine Practice1996; 17(2):320 - 325.
10Lundgren M,Buren J,Ruge T,et al.Glucocorticoids down regulate glucose uptake capacity and insulin-signaling proteins in o-mental but not subcutaneous human adipocytes.J Clin Endocrinol Metab,2004,89(6):2989-2997.
